Novavax's COVID-19-influenza vaccines show strong immune response in older adults, paving the way for regulatory approval.

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

Results showed that the CIC and flu vaccines generated “robust immune responses” across three flu strains (H1N1, H3N2 and B) ...

US biotech Novavax (Nasdaq: NVAX) has reported that its experimental combination COVID-19 and influenza vaccine generated ...

Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 2:00 PM ETCompany ParticipantsJames Patrick Kelly ...

Novavax (NasdaqGS:NVAX) recently reported initial results from its Phase 3 trial for its COVID-19-Influenza Combination and seasonal influenza vaccines, which showed immune responses comparable to ...

COVID-19-influenza combination (CIC) and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza (TNIV) phase 3 ...

Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 ...

Novavax, Inc. (NVAX) on Wednesday said that its COVID-19-Influenza combination and stand-alone Influenza vaccine candidates ...

The Gaithersburg, Md., biotechnology company said Wednesday that results of the initial cohort of vaccines showed both the Covid-19-influenza combination and flu-vaccine candidates induced immune ...

Novavax (NVAX) stock gains as the company reports promising Phase 3 trial results for its COVID-19-Influenza combo vaccine and stand-alone flu shot. Read more here.